Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgical Pathology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.JAMA Oncol. 2017; 3: 1335-1342
- International union of basic and clinical pharmacology. CV. somatostatin receptors: Structure, function, ligands, and new nomenclature.Pharmacol Rev. 2018; 70: 763-835
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.Eur J Nucl Med. 1993; 20: 716-731
- Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.Pancreas. 2016; 45: 187-192
- The epidemiology of metastases in neuroendocrine tumors.Int J Cancer. 2016; 139: 2679-2686
- Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes.Cancer. 2015; 121: 589-597
- Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy.Molecules. 2020; 25
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues.Neuroendocrinology. 2017; 105: 295-309
- Should 68Ga-DOTATATE PET/CT be Performed Routinely in Patients with Neuroendocrine Tumors Before Surgical Resection?.World J Surg. 2020; 44: 604-611
- Somatostatin receptor imaging.Semin Nucl Med. 2002; 32: 84-91
- High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.J Med Imaging Radiat Oncol. 2012; 56: 40-47
- 68Ga-DOTATATE Compared with 111 In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.J Nucl Med. 2016; 57: 872-878
- Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites.J Clin Oncol. 2016; 34: 588-597
- Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors.J Nucl Med. 2018; 59: 66-74
- The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.Pancreas. 2020; 49: 1-33
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging.Neuroendocrinology. 2017; 105: 212-244
- Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.J Surg Oncol. 2020; 121: 480-485
- 68Gallium-DOTATATE positron emission tomography–computed tomography (PET CT) changes management in a majority of patients with neuroendocrine tumors.Surg (United States). 2019; 165: 178-185
- The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors.Pancreas. 2017; 46: 707-714
- Neuroendocrine tumor recurrence: Diagnosis with 68Ga-DOTATATE PET/CT.Radiology. 2014; 270: 517-525
- 64Cu-DOTATATE PET/CT for imaging patients with known or suspected somatostatin receptor-Positive neuroendocrine tumors: Results of the first U.S. prospective, reader-masked clinical trial.J Nucl Med. 2020; 61: 890-896
- The challenge of evaluating response to peptide receptor radionuclide therapy in gastroenteropancreatic neuroendocrine tumors: The present and the future.Diagnostics. 2020; 10: 1-31
- 111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: Impact on krenning scores and effect of tumor burden.J Nucl Med. 2019; 60: 1266-1269
- Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors.N Engl J Med. 2017; 376: 125-135
- SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.Mol Imaging Biol. 2015; 17: 313-318
- 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours.Radiother Oncol. 2019; 141: 108-115
- 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: A systematic review and meta-analysis.Nucl Med Commun. 2019; 40: 1195-1203
- 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol. 2021; 22: 1752-1763
- Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors.Clin Cancer Res. 2017; 23: 4617-4624
- Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.J Clin Oncol. 2005; 23: 2754-2762
- Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies.Surg (United States). 2021; 169: 162-167
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.Eur J Nucl Med Mol Imaging. 2020; 47: 2372-2382
- Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177 lu-dotatate in the phase III netter-1 trial.J Clin Oncol. 2018; 36: 2578-2584
- Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.Eur J Nucl Med Mol Imaging. 2018; 45: 38-46
- NANETS/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy.J Nucl Med. 2020; 61: 222-227
- Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: Safety and survival analysis in 69 patients.J Nucl Med. 2019; 60: 377-385
- Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2015; 42: 176-185
- NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE.J Nucl Med. 2019; 60: 937-943
- Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.Pancreas. 2018; 163: 761-767
- Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.Ann Surg. 2021; 274: e45-e53
- Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1–G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.Ann Surg Oncol. 2016; 23: 981-989
- Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy.J Nucl Med. 2021; 62: 69-72
- Bowel obstruction as a complication of peptide receptor radionuclide therapy (PRRT).J Nucl Med. 2021; 62: 9-10
- Clinical results of radionuclide therapy of neuroendocrine tumours with 90 Y-DOTATATE and tandem 90 Y/177 Lu-DOTATATE: Which is a better therapy option?.Eur J Nucl Med Mol Imaging. 2011; 38: 1788-1797
- Survival after somatostatin based radiopeptide therapy in metastasized gastrinoma.Am J Nucl Med Mol Imaging. 2015; 5: 46-55
- U.S National Library of Medicine. Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer. Clinical Trials.gov.(Accessed October 28, 2022)
- Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and upda.J Clin Oncol. 2020; 38
- Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors.Endocr Relat Cancer. 2022; 29: 225-239
- Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.Sci Rep. 2020; 10: 1-10
- COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET.Ann Oncol. 2018; 29: viii478
Article info
Publication history
Published online: December 13, 2022
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
